Sayda Mahgoub Elbashir

This inventor holds 57 USPTO granted patents and 39 published patent applications, plus 2 CIPO patents and 16 EPO patents, primarily in Nucleic Acid Vaccines (CPC class A61K). Top assignees: Modernatx, Inc., Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Massachusetts Institute of Technology. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sayda Mahgoub Elbashir. Retrieved from https://idiyas.com/inventor/sayda-mahgoub-elbashir

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 57 (Patent Applications = 39)

% Patents Active = 71.9

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 16 (Patent Applications = 29)

Average Co-Inventor Count = 3.7

ph-index = 27

Forward Citations = 2,920(Granted Patents)

Forward Citations (Not Self Cited) = 2,678(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.

patents

14 out of 8,586

Massachusetts Institute of Technology

patents

4. 14 out of 1,628

University of Massachusetts

patents

5. 14 out of 318

Whitehead Institute for Biomedical Research

patents

6. 8 out of 34

Moderna Therapeutics, Inc.

patents

7. 7 out of 466

Alnylam Pharmaceuticals, Inc.

patents

8. 1 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

Nucleic Acids

RNA Vaccines

Chikungunya Virus

HIV RNA

Polynucleotide Modifications

Biologics Production

Oncology Proteins

RNA Interference

VZV Vaccines

In Vivo Production

Protein Engineering

Small RNA Molecules

57 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12502431 - DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS (2025-12-23),

2. 12419957 - Delivery and formulation of engineered nucleic acids (2025-09-23),

3. 12409226 - Delivery and formulation of engineered nucleic acids (2025-09-09),

4. 12364763 - Delivery and formulation of engineered nucleic acids (2025-07-22),

5. 12070495 - HIV RNA vaccines (2024-08-27),

6. 11911474 - Delivery and formulation of engineered nucleic acids (2024-02-27),

7. 11643441 - Nucleic acid vaccines for varicella zoster virus (VZV) (2023-05-09),

8. 11603399 - Long-lived polynucleotide molecules (2023-03-14),

9. 11364292 - CHIKV RNA vaccines (2022-06-21),

10. 11235052 - Chikungunya virus RNA vaccines (2022-02-01),

11. 10898574 - Delivery and formulation of engineered nucleic acids (2021-01-26),

12. 10772975 - Modified Polynucleotides for the production of biologics and proteins associated with human disease (2020-09-15),

13. 10702597 - CHIKV RNA vaccines (2020-07-07),

14. 10675342 - Chikungunya virus RNA vaccines (2020-06-09),

15. 10633656 - RNA interference mediating small RNA molecules (2020-04-28),

Title: The Innovation Journey of Inventor Sayda Mahgoub Elbashir

Introduction:

Sayda Mahgoub Elbashir, a prolific inventor based in Cambridge, MA, has made significant contributions to the field of biotechnology with his remarkable portfolio of 51 patents.

Latest Patents:

1. Nucleic acid vaccines for varicella zoster virus (VZV): Elbashir's groundbreaking work involves nucleic acid vaccines for VZV, incorporating RNA polynucleotides encoding VZV antigens. The patents outline methods for vaccine preparation and usage.

2. Long-lived polynucleotide molecules: Elbashir's invention focuses on the therapeutic use and preparation of long-lived polynucleotides, primary transcripts, and mmRNA molecules.

Career Highlights:

Elbashir has left an indelible mark in companies like Moderna Inc. and the Massachusetts Institute of Technology, where his innovative spirit and expertise have been instrumental in pushing the boundaries of biotechnological advancements.

Collaborations:

Throughout his career, Elbashir has collaborated closely with esteemed colleagues such as Antonin de Fougerolles and Jason P. Schrum, fostering a culture of innovation and excellence in his research endeavors.

Conclusion:

In conclusion, Sayda Mahgoub Elbashir's exceptional talent and dedication to innovation have not only yielded an impressive patent portfolio but have also paved the way for groundbreaking advancements in the realm of biotechnology. His contributions continue to inspire future generations of inventors and researchers in the field.

Profile summary based on public USPTO records.